Gorman J M
Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York 10032, USA.
Depress Anxiety. 1996;4(4):160-8. doi: 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J.
The relationship between depression and anxiety disorders has long been a matter of controversy. The overlap of symptoms associated with these disorders makes diagnosis, research, and treatment particularly difficult. Recent evidence suggests genetic and neurobiologic similarities between depressive and anxiety disorders. Comorbid depression and anxiety are highly prevalent conditions. Patients with panic disorder, generalized anxiety disorder, social phobia, and other anxiety disorders are also frequently clinically depressed. Approximately 85% of patients with depression also experience significant symptoms of anxiety. Similarly, comorbid depression occurs in up to 90% of patients with anxiety disorders. Patients with comorbid disorders do not respond as well to therapy, have a more protracted course of illness, and experience less positive treatment outcomes. One key to successful treatment of patients with mixed depressive and anxiety disorders is early recognition of comorbid conditions. Antidepressant medications, including the selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors, are highly effective in the management of comorbid depression and anxiety. The high rates of comorbid depression and anxiety argue for well-designed treatment studies in these populations.
抑郁症与焦虑症之间的关系长期以来一直存在争议。与这些疾病相关的症状重叠使得诊断、研究和治疗尤为困难。最近的证据表明,抑郁和焦虑症之间存在遗传和神经生物学上的相似性。共病性抑郁和焦虑是非常普遍的情况。患有惊恐障碍、广泛性焦虑症、社交恐惧症和其他焦虑症的患者临床上也经常出现抑郁症状。大约85%的抑郁症患者也会出现明显的焦虑症状。同样,高达90%的焦虑症患者会出现共病性抑郁。患有共病的患者对治疗的反应不佳,病程更长,治疗效果也不太理想。成功治疗混合性抑郁和焦虑症患者的一个关键是早期识别共病情况。抗抑郁药物,包括选择性5-羟色胺再摄取抑制剂、三环类抗抑郁药和单胺氧化酶抑制剂,在治疗共病性抑郁和焦虑方面非常有效。共病性抑郁和焦虑的高发生率表明需要针对这些人群进行精心设计的治疗研究。